Charles Brynelsen Power - 12 Feb 2026 Form 4 Insider Report for Envoy Medical, Inc. (COCH)

Role: Director
Signature: /s/ Andrew Nick as Attorney-in-Fact for Charles Brynelsen pursuant to Power of Attorney previously filed.
Issuer symbol: COCH
Transactions as of: 12 Feb 2026
Net transactions value: +$400,000
Form type: 4
Filing time: 17 Feb 2026, 16:45:18 UTC
Previous filing: 05 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
BRYNELSEN CHARLES	Director	C/O 4875 WHITE BEAR PARKWAY, WHITE BEAR LAKE	/s/ Andrew Nick as Attorney-in-Fact for Charles Brynelsen pursuant to Power of Attorney previously filed.	16 Feb 2026	0001712459

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	COCH	Class A Common Stock	Purchase	$400,000	+1,000,000	+2000%	$0.4000	1,050,000	12 Feb 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	COCH	Warrant (right to buy)	Purchase	$0	+600,000		$0.000000	600,000	12 Feb 2026	Class A Common Stock	600,000	$0.4000	Direct	F2, F3
transaction	COCH	Warrant (right to buy)	Purchase	$0	+1,000,000		$0.000000	1,000,000	12 Feb 2026	Class A Common Stock	1,000,000	$0.4000	Direct	F2, F4
holding	COCH	Stock Option (right to buy)						62,500	12 Feb 2026	Class A Common Stock	62,500	$2.40	Direct	F1
holding	COCH	Stock Option (right to buy)						62,500	12 Feb 2026	Class A Common Stock	62,500	$0.8130	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options to purchase 46,875 shares vest on 10/15/2023, and the remaining 15,625 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months.
F2	Exercisable upon shareholder approval of the issuance of shares of Class A Common Stock underlying the warrants.
F3	The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device.
F4	The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device.